MLN4924 represents an alternative approach to inhibiting Vif: it has a well-characterized mechanism of action; it is highly selective for the NEDD8 E1 (over Sumo and Ubiquitin UBE1); it is validated in mouse models of cancer and currently in clinical trials [20], [21]. This evidence concerns the gene UBA1 and cancer.